Robert N. Raju

1.3k total citations
30 papers, 985 citations indexed

About

Robert N. Raju is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Robert N. Raju has authored 30 papers receiving a total of 985 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Robert N. Raju's work include Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (6 papers) and HER2/EGFR in Cancer Research (6 papers). Robert N. Raju is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (6 papers) and HER2/EGFR in Cancer Research (6 papers). Robert N. Raju collaborates with scholars based in United States, Canada and United Kingdom. Robert N. Raju's co-authors include Lina Asmar, D. Ilegbodu, Kathy S. Albain, Melody Cobleigh, David Loesch, Robert J. Belt, Brian Leyland‐Jones, Lea Fuchs, Robert M. Sayre and Elizabeth Valentine and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Robert N. Raju

30 papers receiving 966 citations

Peers

Countries citing papers authored by Robert N. Raju

Since Specialization

Citations

This map shows the geographic impact of Robert N. Raju's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert N. Raju with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert N. Raju more than expected).

Fields of papers citing papers by Robert N. Raju

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert N. Raju. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert N. Raju. The network helps show where Robert N. Raju may publish in the future.

Co-authorship network of co-authors of Robert N. Raju

This figure shows the co-authorship network connecting the top 25 collaborators of Robert N. Raju. A scholar is included among the top collaborators of Robert N. Raju based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert N. Raju. Robert N. Raju is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	R‐CHOPwith iodine‐131 tositumomab consolidation for advanced stage diffuse largeB‐cell lymphoma (DLBCL):SWOG S0433 2014 ·British Journal of Haematology ·Jonathan W. Friedberg, Joseph M. Unger, Richard Burack, Ajay K. Gopal, Robert N. Raju, Auayporn Nademanee, Mark Kaminski, Hongli Li, Oliver W. Press, Thomas P. Miller, Richard I. Fisher	24
2	A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer 2014 ·International Journal of Oncology ·Allen Lee Cohn, Michael Lahn, (unknown), Ann Cleverly, Celine Pitou, Sunil Kadam, Mark W. Farmen, D. Desaiah, Robert N. Raju, Paul Conkling, Donald Richards	37
3	A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors. 2014 ·Journal of Clinical Oncology ·Donald Richards, Fadi S. Braiteh, Agustin A. García, Crystal S. Denlinger, Paul Conkling, William J. Edenfield, Stephen P. Anthony, Beth A. Hellerstedt, Robert N. Raju, Carlos Becerra, Wael A. Harb, David A. Smith, Charlotte F. McDonagh, (unknown), (unknown), Victor Moyo	33
4	A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies 2013 ·BMC Cancer ·Jonathan W. Goldman, Robert N. Raju, Gregory Gordon, Iman El‐Hariry, (unknown), Vojo Vukovic, Robert Bradley, Michael D. Karol, Yu Chen, Wei Guo, Takayo Inoue, Lee S. Rosen	90
5	Paired Tumor and Normal Whole Genome Sequencing of Metastatic Olfactory Neuroblastoma 2012 ·PLoS ONE ·Glen J. Weiss, Winnie S. Liang, Tyler Izatt, Shilpi Arora, Irene Cherni, Robert N. Raju, Galen Hostetter, Ahmet Kurdoglu, Alexis Christoforides, Shripad Sinari, Angela Baker, Raghu Metpally, Waibhav Tembe, L Taylor Phillips, Daniel D. Von Hoff, David W. Craig, John D. Carpten	28
6	Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer 2009 ·Clinical Oncology ·(unknown), Charles Cunningham, Neil Senzer, Donald Richards, Robert N. Raju, Barry Jones, M. J. Uprichard, John Nemunaitis	75
7	A prospective evaluation of quality of life (QOL) in a phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC) 2009 ·Journal of Clinical Oncology ·Robert N. Raju, Mark A. Socinski, Thomas E. Stinchcombe, (unknown), Darren M. Kocs, Robert M. Jotte, (unknown), Jane Bromund, (unknown), Coleman K. Obasaju	2
8	Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial 2008 ·Journal of Thoracic Oncology ·Mark A. Socinski, Robert N. Raju, Marcus A. Neubauer, David A. Smith, Donald Richards, Michael A. Savin, Robert L. Ruxer, Craig H. Reynolds, Zhan Feng, Jane Bromund, Ruqin Chen, Coleman K. Obasaju	20
9	Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium 2008 ·Investigational New Drugs ·Thomas E. Hutson, Svetislava J. Vukelja, Daniel Atienza, Sanjay Awasthi, (unknown), (unknown), (unknown), (unknown), (unknown), Joseph J. Muscato, Robert N. Raju, Robert L. Ruxer, (unknown), D. Ilegbodu, (unknown), Steven J. Nicol, William R. Berry	4
10	P1-229: The impact of shortened vitamin supplementation lead-in time before pemetrexed (P) in patients with relapsed small-cell lung cancer (SCLC) 2007 ·Journal of Thoracic Oncology ·Mark A. Socinski, Robert N. Raju, Donald Richards, (unknown), Craig H. Reynolds, Ruqin Chen, Jane Bromund, Joseph Treat, Coleman K. Obasaju	1
11	Pemetrexed (P) in relapsed small cell lung cancer (SCLC): Preliminary results of a phase II trial 2007 ·Journal of Clinical Oncology ·Robert N. Raju, Marcus A. Neubauer, Deborah A. Smith, Donald Richards, Lina Asmar, (unknown), (unknown), (unknown), Coleman K. Obasaju, Mark A. Socinski	5
12	Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer 2006 ·Journal of Clinical Oncology ·Nicholas J. Robert, Brian Leyland‐Jones, Lina Asmar, Robert J. Belt, D. Ilegbodu, David Loesch, Robert N. Raju, Elizabeth Valentine, Robert M. Sayre, Melody Cobleigh, Kathy S. Albain, (unknown), Lea Fuchs, Dennis J. Slamon	342
13	Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer 2004 ·Lung Cancer ·Marcus A. Neubauer, David Garfield, (unknown), Robert N. Raju, Deborah Lindquist, (unknown), Myrna M. Khan, Kristi A. Boehm, Lina Asmar	15
14	Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival 2004 ·Journal of Clinical Oncology ·N. J. Robert, Brian Leyland‐Jones, Lina Asmar, Robert J. Belt, D. Ilegbodu, David Loesch, Robert N. Raju, Melody Cobleigh, Kathy S. Albain, (unknown)	28
15	ViVACCy—A Drug Schedule Based on G2 Blockade and Prolonged Infusion of Multiple Tubulin-Binding Agents A Pilot Study 1990 ·Cancer ·Stanley E. Shackney, Reginald P. Pugh, Bernard L. Zidar, Robert N. Raju, Sheryl R. Simon, (unknown), John W. Mucenski	1
16	Radiation-induced leiomyosarcoma of the great vessels presenting as superior vena cava syndrome 1987 ·Cancer ·(unknown), Bernard L. Zidar, (unknown), George J. Magovern, Robert N. Raju, Anthony R. Lupetin, Stanley E. Shackney, Sheryl R. Simon, (unknown), Reginald P. Pugh	18
17	Pseudo-Gaucher Cells in the Bone Marrow of a Patient with Hodgkin’s Disease 1987 ·American Journal of Clinical Pathology ·Bernard L. Zidar, Robert J. Hartsock, Robert Lee, Robert H. Glew, (unknown), Reginald P. Pugh, Robert N. Raju, Stanley E. Shackney	31
18	Treatment of six cases of mesothelioma with doxorubicin and cisplatin 1983 ·Cancer ·Bernard L. Zidar, Reginald P. Pugh, Lewis M. Schiffer, Robert N. Raju, (unknown), (unknown), (unknown), Laurence H. Baker	33
19	Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: Preliminary report of a randomized study 1983 ·Breast Cancer Research and Treatment ·Carl G. Kardinal, Michael C. Perry, Vivian Weinberg, William Wood, Sandra J. Ginsberg, Robert N. Raju, (unknown)	21
20	Lactic Acidosis in Lung Cancer 1983 ·Southern Medical Journal ·Robert N. Raju, (unknown)	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact